Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 5, 2011, Pages 1111-1117

  Waddell, T ^a   Gollins, S ^b   Soe, W ^a   Valle, J ^a   Allen, J ^a   Bentley, D ^a   Morris, J ^b   Lloyd, A ^b   Swindell, R ^a   Taylor, M B ^a   Saunders, M P ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b GLAN CLWYD HOSPITAL   (United Kingdom)

Author keywords

Capecitabine; Metastatic colorectal cancer; Oxaliplatin; Quality of life; Stop and go strategy

Indexed keywords

CAPECITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; INFECTION; INJECTION PAIN; KIDNEY DYSFUNCTION; LETHARGY; LEUKOPENIA; LIVER FUNCTION TEST; MAINTENANCE THERAPY; MALE; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RISK REDUCTION; SHORT COURSE THERAPY; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; QUALITY OF LIFE;

EID: 79955557842     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1322-0     Document Type: Article

References (19)

1. TS Maughan RD James DJ Kerr JA Ledermann MT Seymour C Topham C McArdle D Cain RJ Stephens Medical Research Council Colorectal Cancer Group 2003 Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial Lancet 361 457 464 12583944 10.1016/S0140-6736(03)12461-0 1:CAS:528:DC%2BD3sXhtVahur8%3D (Pubitemid 36173710)
2. RM Goldberg DJ Sargent RF Morton CS Fuchs RK Ramanathan SK Williamson BP Findlay HC Pitot SR Alberts 2004 A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 23 30 14665611 10.1200/JCO.2004.09.046 1:CAS:528:DC%2BD2cXpsVKitbY%3D (Pubitemid 41095110)
3. RM Goldberg DJ Sargent RF Morton CS Fuchs RK Ramanathan SK Williamson BP Findlay HC Pitot S Alberts 2006 Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial J Clin Oncol 24 3347 3353 16849748 10.1200/JCO.2006.06.1317 1:CAS:528:DC%2BD28Xot1Kis7k%3D (Pubitemid 46638888)
4. A de Gramont A Figer M Seymour M Homerin A Hmissi J Cassidy C Boni H Cortes-Funes A Cervantes G Freyer D Papamichael N Le Bail C Louvet D Hendler F de Braud C Wilson F Morvan A Bonetti 2000 Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2938 2947 10944126 (Pubitemid 30644117)
5. J Cassidy S Clarke E Díaz-Rubio W Scheithauer A Figer R Wong S Koski M Lichinitser TS Yang F Rivera F Couture F Sirzén L Saltz 2008 Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 2006 2012 18421053 10.1200/JCO.2007.14.9898 1:CAS:528:DC%2BD1cXlvFaqs7s%3D
6. E Díaz-Rubio J Tabernero A Gómez-España B Massutí J Sastre M Chaves A Abad A Carrato B Queralt JJ Reina J Maurel E González-Flores J Aparicio F Rivera F Losa E Aranda Spanish Cooperative Group for the Treatment of Digestive Tumors Trial 2007 Phase III trial of capecitabine and oxaliplatin (XELOX) vs continuous infusion 5-fluorouracil plus oxaliplatin (FUOX) as first-line therapy in metastatic colorectal cancer: final report of the Spanish TTD group trial J Clin Oncol 25 4224 4230 17548839 10.1200/JCO.2006.09.8467 (Pubitemid 47548562)
7. Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, Adenis A, Faroux R, Rebischung C, Douillard J (2007) Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC). J Clin Oncol 25;18S (suppl abstract 4029)
8. S Giacchetti B Perpoint R Zidani N Le Bail R Faggiuolo C Focan P Chollet JF Llory Y Letourneau B Coudert F Bertheaut-Cvitkovic D Larregain-Fournier A Le Rol S Walter R Adam JL Misset F Lévi 2000 Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer J Clin Oncol 18 136 147 10623704 1:CAS:528:DC%2BD3cXmtFSqsw%3D%3D (Pubitemid 30036347)
9. C Tournigand A Cervantes A Figer G Lledo M Flesch M Buyse L Mineur E Carola PL Etienne F Rivera I Chirivella N Perez-Staub C Louvet T André I Tabah-Fisch A de Gramont 2006 OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer: a GERCOR study J Clin Oncol 24 394 400 16421419 10.1200/JCO.2005.03.0106 1:CAS:528:DC%2BD28XhsFSku7w%3D (Pubitemid 46630458)
10. Maindrault-Goebel F, Lledo G, Chibaudel B, Mineur L, Andre T, Bennamoun M, Mabro M, Artru P, Louvet C, De Gramont A (2006) OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): a GERCOR study. J Clin Oncol 24 (18S; abstract 3504)
11. Labianca R, Floriani I, Cortesi E, Isa L, Zaniboni A, Marangolo M, Frontini L, Barni S, Beretta GD, Sobrero A, Italian Group for the Study of Digestive Tract Cancers (2006) Alternating versus continuous "FOLFIRI" in advanced colorectal cancer (ACC): A randomized "GISCAD" trial J Clin Oncol 24 (18S; abstract 3505)
12. PM Hoff R Ansari G Batist J Cox W Kocha M Kuperminc J Maroun D Walde C Weaver E Harrison HU Burger B Osterwalder AO Wong R Wong 2001 Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J Clin Oncol 19 2282 2292 11304782 1:CAS:528:DC%2BD3MXjsFeqsrw%3D (Pubitemid 32366981)
13. E Van Cutsem C Twelves J Cassidy D Allman E Bajetta M Boyer R Bugat M Findlay S Frings M Jahn J McKendrick B Osterwalder G Perez-Manga R Rosso P Rougier WH Schmiegel JF Seitz P Thompson JM Vieitez C Weitzel P Harper Xeloda Colorectal Cancer Study Group 2001 Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study J Clin Oncol 19 4097 4106 11689577 (Pubitemid 33049527)
14. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
15. NK Aaronson S Ahmedzai B Bergman M Bullinger A Cull NJ Duez A Filiberti H Flechtner SB Fleishman JC de Haes 1993 The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 365 376 8433390 10.1093/jnci/85.5.365 1:STN:280:DyaK3s7msVarsQ%3D%3D (Pubitemid 23073154)
16. MA Sprangers A te Velde NK Aaronson 1999 The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on Quality of Life Eur J Cancer 35 238 247 10448266 10.1016/S0959-8049(98) 00357-8 1:STN:280:DyaK1Mznslektw%3D%3D (Pubitemid 29136774)
17. D Cunningham S Pyrhonen RD James CJ Punt TF Hickish R Heikkila TB Johannesen H Starkhammar CA Topham L Awad C Jacques P Herait 1998 Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 352 1413 1418 9807987 10.1016/S0140-6736(98)02309-5 1:CAS:528:DyaK1cXnsVSmsLs%3D (Pubitemid 28510874)
18. TJ Hobday JW Kugler MR Mahoney DJ Sargent JA Sloan TR Fitch JE Krook MJ O'Connell JA Mailliard MT Tirona LK Tschetter CD Cobau RM Goldberg 2002 Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma J Clin Oncol 20 4574 4580 12454115 10.1200/JCO.2002.08.535 1:CAS:528: DC%2BD38XovVeisLs%3D (Pubitemid 35402961)
19. A de Gramont M Buyse JC Abrahantes T Burzykowski E Quinaux A Cervantes A Figer G Lledo M Flesch L Mineur E Carola PL Etienne F Rivera I Chirivella N Perez-Staub C Louvet T André I Tabah-Fisch C Tournigand 2007 Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer J Clin Oncol 25 3224 3229 17664470 10.1200/JCO.2006.10.4380 (Pubitemid 47325605)